Massachusetts S3102 mandates coverage for biomarker testing in health insurance policies.

Massachusetts S3102 amends the General Laws to require health insurance policies to cover biomarker testing. This testing is defined as the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, including single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing. The bill specifies that biomarker testing must be covered for diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when supported by medical and scientific evidence.

Massachusetts S3102 mandates coverage for biomarker testing in health insurance policies.

Massachusetts S3102 amends the General Laws to require health insurance policies to cover biomarker testing. This testing is defined as the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker, including single-analyte tests, multi-plex panel tests, protein expression, and whole exome, whole genome, and whole transcriptome sequencing. The bill specifies that biomarker testing must be covered for diagnosis, treatment, appropriate management, or ongoing monitoring of an enrollee's disease or condition when supported by medical and scientific evidence.